Remicade (infliximab) - J&J
Amjevita (adalimumab-atto) - Amgen, Daiichi Sankyo, Orion Corp
Avsola (infliximab-axxq) - Amgen
Hyrimoz (adalimumab-adaz) - Sandoz
Hulio (adalimumab-fkjp) - Fujifilm Kyowa Kirin Biologics, Biocon
Renflexis (infliximab-abda) - Yuhan Corp, Biogen, Ewopharma, Samsung, Organon
CAMEO: Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease (clinicaltrials.gov) - Oct 20, 2026 - P4 | N=1270 | Active, not recruiting | Sponsor: Connecticut Children's Medical Center | Recruiting ➔ Active, not recruiting | N=900 ➔ 1270 
Enrollment change • Enrollment closed • Crohn's disease • Gastroenterology • Genetic Disorders • Immunology • Inflammatory Bowel Disease • Oncology
http://clinicaltrials.gov/ct2/show/NCT05781152
 
Oct 20, 2026
 
Prev Next